Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$9.46 – $22.43
13% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.56B | $1.73B | $1.50B | $1.95B | $2.12B | $2.26B | $2.41B | $2.39B |
| Cost of revenue | $1.21B | $1.53B | $1.35B | $1.69B | $1.84B | $1.71B | $1.05B | $2.18B |
| Gross profit | $350.5M | $201.0M | $153.2M | $259.6M | $275.7M | $548.4M | $1.36B | $210.8M |
| Gross margin | 22.5% | 11.6% | 10.2% | 13.3% | 13.0% | 24.3% | 56.6% | 8.8% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $186.3M | $201.0M | $153.2M | $259.6M | $275.7M | $259.2M | $256.8M | $210.8M |
| EBITDA | $224.5M | $292.0M | $364.8M | $478.4M | $514.5M | $522.0M | $557.3M | $520.0M |
| Net income | $115.1M | $108.7M | $101.0M | $157.8M | $178.5M | $155.1M | $145.4M | $91.3M |
| Net margin | 7.4% | 6.3% | 6.7% | 8.1% | 8.4% | 6.9% | 6.0% | 3.8% |
| EPS (diluted) | 0.51 | 0.48 | 0.45 | 0.69 | 0.79 | 0.69 | 0.64 | 0.40 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.4B | $0.72 | $0.71–$0.73 | 1 |
| 2027 | $3.0B | $0.88 | $0.87–$0.90 | 1 |
| 2028 | $3.1B | $0.99 | $0.98–$1.01 | 1 |
| 2029 | $3.5B | $1.12 | $1.10–$1.14 | 1 |
Forward consensus · source: Financial Modeling Prep
AMPLIFON SPA MILANO
No one on the platform currently holds AMFPF.
No tracked institution reports a position in AMFPF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-19 | $0.2900 | 2026-05-20 |
| 2025-05-20 | $0.2900 | 2025-05-21 |
| 2024-05-20 | $0.2900 | 2024-05-22 |
| Execution date | Ratio |
|---|---|
| 2006-05-08 | 10-for-1 |
No one on the platform has traded AMFPF yet.
| +0.00% |
| $2.6B |
| — |
| CZMWYCarl Zeiss Meditec AG | $30.38 | -1.94% | $2.7B | — |
| MAHLYMediPal Holdings Corporation | $16.28 | +0.00% | $3.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 17.8× earnings vs its 46.9× historical median P/E.
Fair value ≈ $29.61 · price $11.21 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.